Has cellular age reversal actually been demonstrated in humans?

ER-100 has entered human testing, but entering a trial is not demonstrating rejuvenation. The therapy uses controlled expression of three reprogramming factors—OCT4, SOX2 and KLF4—to investigate whether damaged retinal cells can regain function. The sponsor reports visual-function benefits in animal research, and announced first human dosing in June 2026. The initial human study concerns optic neuropathies and is primarily a safety and tolerability investigation.[1][2]

A change in an aging-related molecular pattern, a change in vision and an increase in lifespan are different claims. Even a positive eye result would not establish safe rejuvenation of the whole body. Researchers need to assess whether the intended cells behave normally, whether any functional improvement lasts and whether delayed adverse effects arise. At this stage, the appropriate description is an experimental test of epigenetic restoration in a specific tissue, with human efficacy still unestablished.[1][2]